Jonathan Bernstein, AAAAI 2021: Final results from the HELP Study
touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the findings from the HELP study, investigating lanadelumab for the prevention of hereditary angioedema (HAE) attacks.
The abstract ‘Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study.’ (ABSTRACT NUMBER: 462) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions:
- What did the findings of the HELP study teach us about the efficacy and safety of lanadelumab for the prevention of HAE attacks? (0:21)
- What was the rationale for investigating the efficacy of lanadelumab in HAE patients with and without previous use of long-term prophylaxis? (2:02)
- What were the findings of this analysis and what are their implications for clinical practice? (3:09)
Disclosures: Jonathan Bernstein has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
